Takeda commits to deliver 50 million doses of Moderna’s COVID-19 vaccine in Japan

pharmafile | October 29, 2020 | News story | Manufacturing and Production, Sales and Marketing COVID-19, Japan, Moderna, Takeda, Vaccine 

Takeda has made a commitment with Japan’s Ministry of Health, Labor and Welfare (MHLW) to deliver 50 million doses of Moderna’s COVID-19 mRNA-1273 vaccine, the company announced.

The commitment is dependent on whether the candidate can secure regulatory approval from the MHLW. If the vaccine is successful, Takeda will carry out importing and distribution duties to roll out the candidate to Japan’s citizens in the first half of next year.

This isn’t the first partnership of its kind that Takeda has forged to tackle the COVID-19 pandemic, having synced up with Novavax in August to aid in the development, manufacturing and commercialisation of the latter’s vaccine candidate for the virus.

“Takeda is collaborating with the Japanese Government and vaccine developers to provide rapid and sustained access to COVID-19 vaccines in Japan,” remarked Rajeev Venkayya, President of Takeda’s Global Vaccine Business Unit at Takeda. “We have chosen to work with Novavax and Moderna, both of which have promising vaccine candidates, and will continue to support the global response to COVID-19.”

The news follows Moderna’s recent announcement that its Phase 3 clinical trial to test a 100 µg dose of its vaccine had fulfilled its enrolment target, recruiting 30,000 participants.

Matt Fellows

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …


FDA committee votes in favour of Pfizer’s RSV vaccine for maternal immunisation

Pfizer has announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) from the …

FDA grants Priority Review for Takeda’s cTTP treatment

Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has …

Latest content